Genes and Cancer
John Wiley & Sons Ltd (Verlag)
978-0-471-92583-5 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
Despite tremendous efforts, there has been little improvement in the overall survival of patients with cancer over the last 30 years. Whilst changes in the management of certain tumours, including lymphomas, leukaemias and testis have produced dramatic improvements in survival, these tumours are rare and so have contributed little to the overall picture. Although there is no doubt that a combination of reducing smoking and dietary alteration would significantly result in a lower cancer incidence and therefore increased survival, it is likely that prevention strategies are going to have little immediate impact in the overall mortality of cancer as we enter the next century. Thus there is a need for the identification and application of new therapeutic strategies. For many cancers a number of factors have been identified which are of prognostic importance. These include patient performance status; disease extent and response to cytotoxic therapy. It is clear however, that considerable heterogeneity in tumour responses are observed, even among patients with a similar tumour.
These data suggest that biological properties inherent within the tumour cells themselves may be of prognostic importance. These properties include the expression of drug or radiation resistant genes; specific and nonspecific chromosomal abnormalities and alteration in the expression of a range of oncogenes.
Part 1 Oncogenes: oncogenes as clinical tools, William Gullick and Karol Sikora; the c-ras oncogene, Nick Lemoine; the c-myc oncogene, Gerard Evan; the N-myc oncogene and neuroblastoma, John Kemshead; the c-myb oncogene and its regulation, E.Premkumar Reddy; c-abl and leukaemia, Ralph B.Arlinghaus; c-src - structure and function, Kentaro Semba and Kumao Toyoshima; oncogenes and metastasis, Suzanne Eccles. Part 2 Gene control: inherited cancer syndromes, Bruce Ponder; transcription factors, Matthew Ellis; modulation of transcription factors by oncogenes, Yoshiaki Ito; mitochondria in cancer cells, Lan Bo Chen; viral trans-activating genes, Irwin S.Chen. Part 3 Molecular therapy - antibodies: designer antibodies, John Adair; antibodies to synthetic peptides, Paul Sheppard; targeted monoclonal antibodies, Richard Begent; immunotherapy with monoclonal antibodies, Aga Epenetos; endothelial cell attack as a novel approach to cancer therapy, Julie Denekamp. Part 4 Molecular therapy - drug resistance: drug resistance, John Smyth; the cell membrane and drug resistance, Jane Plumb and Stan Kaye; DNA repair and drug resistance, Adrian Harris; flow cytometry and drug resistance, David Hedley. Part 5 Molecular therapy - growth factors and receptors: tumour growth factors, Paul Stroobant; the bradykinin receptor, Ruth Roberts; gonadotrophin releasing hormone agonists, Jonathan Waxman and Abdul Quayum; inhibitors of growth factors, William Gullick. Part 5 Tumour biology: gene rearrangement in B-cell lymphomas, David Cunningham and Thomas Hickish; gene rearrangement studies in T-cell lymphomas, Michael Brada; colorectal cancer and familial adenomatous polyposis, Nigel Spurr; lung cancer, Desmond Carney; the biology of metastases, Peter Alexander; bone marrow transplantation, Nicholas James.
| Erscheint lt. Verlag | 22.8.1990 |
|---|---|
| Zusatzinfo | 70 line drawings, 8 half-tones, 32 tables, index |
| Verlagsort | Chichester |
| Sprache | englisch |
| Maße | 51 x 73 mm |
| Gewicht | 750 g |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
| Studium ► 2. Studienabschnitt (Klinik) ► Humangenetik | |
| ISBN-10 | 0-471-92583-7 / 0471925837 |
| ISBN-13 | 978-0-471-92583-5 / 9780471925835 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
